Pyelolithotomy in a patient with Glanzmann thrombasthenia and antiglycoprotein IIb/IIIa antibodies: The shortest possible duration of treatment with recombinant activated factor VII and platelet transfusions

Turkish Journal of Pediatrics

Volumn 45, Issue 1, 2003, Pages 64-66

  Devecioǧlu, Ömer ^a   Ünüvar, Ayşegül ^a   Anak, Sema ^a   Bilge, Ilmay ^b   Ander, Haluk ^a   Ziylan, Orhan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Alloimmunization; Glanzmann thrombasthenia; Hematuria; Platelet; rVIIa; Surgery

Indexed keywords

ALLOANTIBODY; FIBRIN ANTIBODY; FIBRINOGEN; HEMOGLOBIN; HLA ANTIGEN; PROTHROMBIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOCYTE ANTIBODY; THROMBOCYTE CONCENTRATE;

ANTIBODY DETECTION; ARTICLE; BLEEDING; BLEEDING TIME; CASE REPORT; CONSANGUINEOUS MARRIAGE; ERYTHROCYTE TRANSFUSION; FLOW CYTOMETRY; GLANZMANN DISEASE; HEMATURIA; HOSPITAL ADMISSION; HUMAN; HYPOVOLEMIC SHOCK; INTRAOPERATIVE PERIOD; MALE; NEPHROLITHIASIS; PATIENT MONITORING; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; PROTHROMBIN TIME; PYELOLITHOTOMY; SCHOOL CHILD; THROMBOCYTE TRANSFUSION; TIME; TREATMENT OUTCOME;

CHILD, PRESCHOOL; FACTOR VIIA; HUMANS; MALE; PLATELET TRANSFUSION; THROMBASTHENIA;

EID: 0345700346     PISSN: 00414301     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Tengborn L, Petruson B. A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa (Letter). Thromb Haemost 1996; 75: 981.
2. Poon M-C, d'Orion R and the International Registry on Recombinant Factor VIIa, and Congenital Platelet Disorders Group. Recombinant activated factor VII (NovoSeven®) treatment of platelet-related bleeding disorders. Blood Coagul Fibrinolysis 2000; 11 (Suppl): 55-68.
3. d'Orion R, Menart C, Trzeciak MC, et al. Use of recombinant factor VIIa in 3 patients with inherited type 1 Glanzmann's thrombasthenia undergoing invasive procedures. Thromb Haemost 2000; 83: 644-647.
4. Wielenga JJ, Siebel Y, van Buuren HR, et al. Use of recombinant factor VIIa and HLA matched platelets to prevent bleeding during and after major surgery in a patient with Glanzmann's thrombasthenia (Abstract). Haemophilia 1998; 4: 299.
5. Lusher J, Ingerslev J, Roberts H, Hedner U. Clinical experience with recombinant factor VIIa. Blood Coagul Fibrinolysis 1998; 9 (Suppl): 119-128.
6. Kessler CM. New products for managing inhibitors to coagulation factors: a focus on recombinant factor VIIa concentrate. Curr Opin Hematol 2000; 7: 408-413.
7. Hedner U. NovoSeen as a universal haemostatic agent. Blood Coagul Fibrinolysis 2000; 11 (Suppl): 107-111.
8. Poon M-C, Demers C, Jobin F, Wu JW. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood 1999; 94: 3951-3953.
9. Peters M, Heijboer H. Treatment of a patient with Bernard-Soulier syndrome and recurrent nosebleeds with recombinant factor VIIa (Letter). Thromb Haemost 1998; 80: 352.
10. Fressinaud E, Sigaud-Fix M, Le Boterff C, Piot B. Use of recombinant factor VIIa (NovoSeven®) for dental extraction in a patient affected by platelet-type (pseudo-) von Willebrand disease (Abstract). Haemophilia, 1998; 4: 299.
11. Révész T, Arets B, Bierings M, van den Bos C, Duval E. Recombinant factor VIIa in severe uremic bleeding (Letter): Thromb Haemost 1998; 80: 353.
12. Meijer K, Sieders E, Slooff MJ, de WolfJTh, van der Meer J. Effective treatment of severe bleeding due to acquired thrombocytopathia by single dose administration of activated recombinant factor VII (Letter). Thromb Haemost 1998; 80: 204.